Biotechnology News and Research

RSS

U.Va, Coulter Foundation partner for translational research in biomedical engineering

The University of Virginia and the Wallace H. Coulter Foundation have teamed to create a $20 million endowment to foster research collaboration between biomedical engineers and clinicians, with the goal of developing new technologies to improve patient care and human health.

3 May 2011

Astex earns GBP5.9 M milestone payment from GSK for fragment-based screening platform

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009.

3 May 2011

JPO issues patent to Silence Therapeutics' RNAi technology

Silence Therapeutics plc announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.

3 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

FDA clears ITI's FilmArray RP assay for respiratory virus detection

Idaho Technology, Inc. announced today that the U.S. Food and Drug Administration has issued a 510(k) clearance for the FilmArray instrument and the FilmArray Respiratory Panel.

3 May 2011

Sanofi Pasteur, EnGen Bio and Dyadic Nederland sign research deal for vaccine development

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the biopharmaceutical, biofuels and industrial enzyme industries, announced today that its research and development subsidiary, Dyadic Nederland B.V., has entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc.

3 May 2011

PAREXEL third quarter revenue increases 3.5% to $301.4 million

PAREXEL International Corporation today announced its financial results for the third quarter ended March 31, 2011.

From Parexel 3 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Teva signs definitive agreement to acquire Cephalon shares for $6.8 billion

Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

2 May 2011

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.

2 May 2011

Talecris, Grifols enter 'Consent Agreement' with FTC Staff

Grifols, S.A. and Talecris Biotherapeutics Holdings Corporation, announced today that they have signed a "Consent Agreement" with the Staff of the Bureau of Competition of the US Federal Trade Commission by means of which the conditions for the merger transaction between both companies are agreed.

2 May 2011

LSI announces publication of Emerging Medtech Companies report

Life Science Intelligence, a leading medical technology market intelligence firm, has announced the publication of its Report on Emerging Medtech Companies in Q1 2011.

30 Apr 2011

C3 Jian, West China School of Stomatology to create joint CRC to test oral healthcare products

C3 Jian, Inc.'s Board of Directors today announced that the Company has signed an agreement with the West China School of Stomatology at Sichuan University to create a joint Clinical Research Centre to test new oral healthcare products in human clinical trials.

30 Apr 2011

Mary Ann Liebert introduces new videojournal on minimally invasive surgery

Videoscopy-, a groundbreaking new videojournal to complement the peer-reviewed monthly publication, Journal of Laparoendoscopic & Advanced Surgical Techniques has been launched by Mary Ann Liebert, Inc., publishers.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

Oncothyreon prices underwritten public offering of common stock

Oncothyreon Inc. today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Oncothyreon, will be approximately $37.4 million.

29 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

29 Apr 2011

UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company's proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant funding by the Massachusetts Life Sciences Center.

29 Apr 2011

GHRI founder earns Baxter-AUPHA recognition for Health Services Research

In recognition of his significant contributions to studying how best to provide health care, Edward H. Wagner, MD, MPH, has been named the 2011 recipient of the William B. Graham Prize for Health Services Research.

From Baxter International Inc. 29 Apr 2011